JP2013533745A5 - - Google Patents

Download PDF

Info

Publication number
JP2013533745A5
JP2013533745A5 JP2013518791A JP2013518791A JP2013533745A5 JP 2013533745 A5 JP2013533745 A5 JP 2013533745A5 JP 2013518791 A JP2013518791 A JP 2013518791A JP 2013518791 A JP2013518791 A JP 2013518791A JP 2013533745 A5 JP2013533745 A5 JP 2013533745A5
Authority
JP
Japan
Prior art keywords
norovirus
chimeric
strain
vlp
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013518791A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013533745A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/042979 external-priority patent/WO2012006293A1/en
Publication of JP2013533745A publication Critical patent/JP2013533745A/ja
Publication of JP2013533745A5 publication Critical patent/JP2013533745A5/ja
Pending legal-status Critical Current

Links

JP2013518791A 2010-07-06 2011-07-05 ノロウイルスに由来する免疫原性組成物および方法 Pending JP2013533745A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36158110P 2010-07-06 2010-07-06
US61/361,581 2010-07-06
PCT/US2011/042979 WO2012006293A1 (en) 2010-07-06 2011-07-05 Norovirus derived immunogenic compositions and methods

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016000962A Division JP6351641B2 (ja) 2010-07-06 2016-01-06 ノロウイルスに由来する免疫原性組成物および方法

Publications (2)

Publication Number Publication Date
JP2013533745A JP2013533745A (ja) 2013-08-29
JP2013533745A5 true JP2013533745A5 (enExample) 2014-08-14

Family

ID=44628871

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2013518791A Pending JP2013533745A (ja) 2010-07-06 2011-07-05 ノロウイルスに由来する免疫原性組成物および方法
JP2016000962A Active JP6351641B2 (ja) 2010-07-06 2016-01-06 ノロウイルスに由来する免疫原性組成物および方法
JP2018030649A Withdrawn JP2018086020A (ja) 2010-07-06 2018-02-23 ノロウイルスに由来する免疫原性組成物および方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2016000962A Active JP6351641B2 (ja) 2010-07-06 2016-01-06 ノロウイルスに由来する免疫原性組成物および方法
JP2018030649A Withdrawn JP2018086020A (ja) 2010-07-06 2018-02-23 ノロウイルスに由来する免疫原性組成物および方法

Country Status (8)

Country Link
US (3) US20130171185A1 (enExample)
EP (2) EP2591097A1 (enExample)
JP (3) JP2013533745A (enExample)
CN (1) CN103154242B (enExample)
AU (1) AU2011276328C1 (enExample)
CA (1) CA2804501C (enExample)
MX (1) MX2013000163A (enExample)
WO (1) WO2012006293A1 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2646669T3 (es) 2010-07-06 2017-12-14 Glaxosmithkline Biologicals Sa Procedimientos de aumento de una respuesta inmunitaria mediante el suministro de ARN
ES2557382T3 (es) 2010-07-06 2016-01-25 Glaxosmithkline Biologicals Sa Liposomas con lípidos que tienen un valor de pKa ventajoso para el suministro de ARN
EP2591114B1 (en) 2010-07-06 2016-06-08 GlaxoSmithKline Biologicals SA Immunisation of large mammals with low doses of rna
LT4226941T (lt) 2010-08-31 2025-01-10 Glaxosmithkline Biologicals Sa Pegilintos liposomos, skirtos imunogeną koduojančios rnr pristatymui
WO2012051211A2 (en) 2010-10-11 2012-04-19 Novartis Ag Antigen delivery platforms
EP2729165B1 (en) * 2011-07-06 2017-11-08 GlaxoSmithKline Biologicals SA Immunogenic combination compositions and uses thereof
CN109045294A (zh) * 2013-01-10 2018-12-21 思齐乐 流感病毒免疫原性组合物及其应用
US9975923B2 (en) 2013-03-15 2018-05-22 The University Of North Carolina At Chapel Hill Methods and compositions for norovirus blockade epitopes
EP2970395A4 (en) * 2013-03-15 2017-03-29 The University of North Carolina At Chapel Hill Methods and compositions for norovirus blockade epitopes
US20160038586A1 (en) * 2014-08-07 2016-02-11 Medigen Biotechnology Corp. Virus-like Particle Vaccines
EA201792512A1 (ru) 2015-06-12 2018-06-29 Вэксарт, Инк. Составы для доставки антигенов респираторного синтициального вируса и норовируса в тонкий кишечник
CN107034198B (zh) 2015-07-15 2021-03-09 长春百克生物科技股份公司 一种嵌合诺如病毒p颗粒及其制备和应用
WO2017160124A2 (ko) * 2016-03-18 2017-09-21 연세대학교 산학협력단 노로 바이러스 백신을 생산하기 위한 재조합 발현 벡터
KR101915740B1 (ko) 2016-03-18 2018-11-06 (주)인테라 목적 단백질의 발현 효율을 증진시키기 위한 신규한 펩타이드 및 이를 포함하는 융합 단백질
EP4631970A3 (en) * 2016-05-04 2026-01-07 CureVac SE Nucleic acid molecules and uses thereof
US11708574B2 (en) 2016-06-10 2023-07-25 Myriad Women's Health, Inc. Nucleic acid sequencing adapters and uses thereof
WO2018064486A1 (en) 2016-09-29 2018-04-05 Counsyl, Inc. Noninvasive prenatal screening using dynamic iterative depth optimization
US10968447B2 (en) 2017-01-31 2021-04-06 Myriad Women's Health, Inc. Methods and compositions for enrichment of target polynucleotides
WO2018144217A1 (en) 2017-01-31 2018-08-09 Counsyl, Inc. Methods and compositions for enrichment of target polynucleotides
CA3056812C (en) 2017-03-23 2022-11-29 Medicago Inc. Norovirus fusion proteins and vlps comprising norovirus fusion proteins
CA3057589A1 (en) 2017-03-24 2018-09-27 Myriad Women's Health, Inc. Copy number variant caller
EP3600397A4 (en) * 2017-03-28 2021-01-27 Children's Hospital Medical Center NOROVIRUS PARTICLE VACCINES AND THEIR MANUFACTURING AND USE PROCEDURES
WO2019104439A1 (en) 2017-11-30 2019-06-06 Medicago Inc. Modified norovirus vp1 proteins and vlps comprising modified norovirus vp1 proteins
JP6713013B2 (ja) * 2018-03-06 2020-06-24 株式会社イーダブルニュートリション・ジャパン 貝類のノロウイルス不活化方法
CA3106471A1 (en) * 2018-07-13 2020-01-16 Medicago Inc. Modified norovirus vp1 proteins and vlps comprising modified norovirus vp1 proteins
MX2021011059A (es) * 2019-03-12 2021-10-13 Icon Genetics Gmbh Particulas tipo norovirus con estabilidad mejorada.
WO2021140524A1 (en) * 2020-01-08 2021-07-15 Bharat Biotech International Limited Viral vaccine compositions and methods of preparations thereof
CN114316033A (zh) * 2020-09-29 2022-04-12 香港理工大学深圳研究院 一种特异性识别诺如病毒的单克隆抗体及制备方法与应用
CN115161343B (zh) * 2021-04-01 2024-06-04 苏州相奕生物技术有限公司 一种重组腺病毒表达载体及以其制备的多价诺如病毒疫苗
JP2024540061A (ja) * 2021-10-27 2024-10-31 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア ノロウイルスワクチン及び使用法
WO2023176206A1 (ja) 2022-03-18 2023-09-21 デンカ株式会社 リンカーにより連結されたカプシドタンパク質を含むウイルス様粒子
WO2024144262A1 (ko) * 2022-12-27 2024-07-04 (주)한국바이오셀프 노로바이러스 gi mrna를 포함하는 백신 조성물
WO2024144272A1 (ko) * 2022-12-27 2024-07-04 (주)한국바이오셀프 노로바이러스 gii mrna를 포함하는 백신 조성물
CN118126202B (zh) * 2024-05-07 2024-07-30 上海瑞宙生物科技有限公司 一种诺如病毒类病毒颗粒及其应用

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0114787B1 (de) 1983-01-25 1991-09-25 Ciba-Geigy Ag Neue Peptidderivate
US6090406A (en) 1984-04-12 2000-07-18 The Liposome Company, Inc. Potentiation of immune responses with liposomal adjuvants
US5916588A (en) 1984-04-12 1999-06-29 The Liposome Company, Inc. Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
CA1324969C (en) 1988-05-06 1993-12-07 Jeffrey R. Shuster High level expression of proteins in yeast
AU631377B2 (en) 1988-08-25 1992-11-26 Liposome Company, Inc., The Affinity associated vaccine
US6572862B1 (en) 1989-11-08 2003-06-03 Baylor College Of Medicine Methods and reagents to detect and characterize Norwalk and related viruses
US5153312A (en) 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
US5340740A (en) 1992-05-15 1994-08-23 North Carolina State University Method of producing an avian embryonic stem cell culture and the avian embryonic stem cell culture produced by the process
CA2138997C (en) 1992-06-25 2003-06-03 Jean-Paul Prieels Vaccine composition containing adjuvants
JPH08500250A (ja) 1992-09-07 1996-01-16 ベイラー・カレッジ・オブ・メディシン ノーウォークおよび関連ウイルスを検出し、かつ特徴付けるための方法並びに試薬
US5776468A (en) 1993-03-23 1998-07-07 Smithkline Beecham Biologicals (S.A.) Vaccine compositions containing 3-0 deacylated monophosphoryl lipid A
GB9326174D0 (en) 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
FR2726003B1 (fr) 1994-10-21 2002-10-18 Agronomique Inst Nat Rech Milieu de culture de cellules embryonnaires totipotentes aviaires, procede de culture de ces cellules, et cellules embryonnaires totipotentes aviaires
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
DK1005368T3 (da) 1997-03-10 2010-01-04 Ottawa Hospital Res Inst Anvendelse af nukleinsyrer, der indeholder ikke-metyleret CpG dinukleotid i kombination med alun som hjælpestoffer
US6818222B1 (en) 1997-03-21 2004-11-16 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
US6299881B1 (en) 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
US6348450B1 (en) 1997-08-13 2002-02-19 The Uab Research Foundation Noninvasive genetic immunization, expression products therefrom and uses thereof
AU1145699A (en) 1997-09-05 1999-03-22 Smithkline Beecham Biologicals (Sa) Oil in water emulsions containing saponins
GB9725084D0 (en) 1997-11-28 1998-01-28 Medeva Europ Ltd Vaccine compositions
CA2312900A1 (en) 1997-12-02 1999-06-10 Powderject Vaccines, Inc. Transdermal delivery of particulate vaccine compositions
FR2771751B1 (fr) 1997-12-03 2000-05-26 Assist Publ Hopitaux De Paris Erythrovirus et ses applications
IL137809A0 (en) 1998-02-12 2001-10-31 American Cyanamid Co Pneumococcal and meningococcal vaccines formulated with interleukin-12
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
WO1999052549A1 (en) 1998-04-09 1999-10-21 Smithkline Beecham Biologicals S.A. Adjuvant compositions
US6562798B1 (en) 1998-06-05 2003-05-13 Dynavax Technologies Corp. Immunostimulatory oligonucleotides with modified bases and methods of use thereof
KR100629028B1 (ko) 1998-10-16 2006-09-26 글락소스미스클라인 바이오로지칼즈 에스.에이. 애쥬번트 시스템 및 백신
AU780231B2 (en) 1998-11-10 2005-03-10 University Of North Carolina At Chapel Hill, The Virus vectors and methods of making and administering the same
KR100771402B1 (ko) 1999-06-22 2007-10-30 국립감염증연구소장이 대표하는 일본국 Srsv 검출 킷트
HUP0202885A3 (en) 1999-09-24 2004-07-28 Smithkline Beecham Biolog Vaccines
TR200200777T2 (tr) 1999-09-24 2002-09-23 Smithkline Beecham Biologicals S.A. Polioksietilen alkil eteri veya esteriyle en az bir iyonik olmayan yüzey aktif maddeli adjuvant.
US20010044416A1 (en) 2000-01-20 2001-11-22 Mccluskie Michael J. Immunostimulatory nucleic acids for inducing a Th2 immune response
ATE318923T1 (de) 2000-06-01 2006-03-15 Univ North Carolina Doppelsträngige parvovirus-vektoren
SI1354204T2 (sl) 2000-06-15 2010-09-30 Novartis Vaccines & Diagnostic Hcv antigen antitelo kombinacijska analiza
JP2002020399A (ja) 2000-07-10 2002-01-23 Osaka Prefecture ノルウォークウイルス(nv)を認識するモノクローナル抗体
AU2001294750C1 (en) 2000-09-26 2008-09-18 Idera Pharmaceuticals, Inc. Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes
DK1372708T3 (da) 2001-02-13 2008-10-20 Us Gov Sec Army Vaccine til transkutan immunisering mod rejsediarre
JP2004529906A (ja) 2001-03-19 2004-09-30 イオマイ コーポレイシヨン 経皮的免疫賦活
GB0123580D0 (en) 2001-10-01 2001-11-21 Glaxosmithkline Biolog Sa Vaccine
GB0123756D0 (en) 2001-10-03 2001-11-21 King S College London A novel chaperone-type of adjuvant for vaccination - Basic 1
WO2003035836A2 (en) 2001-10-24 2003-05-01 Hybridon Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends
FR2832423B1 (fr) 2001-11-22 2004-10-08 Vivalis Systeme d'expression de proteines exogenes dans un systeme aviaire
WO2003068925A2 (en) 2002-02-11 2003-08-21 Mosca Joseph D Production of a protein delivery system for in vivo therapeutic treatment
FR2836924B1 (fr) 2002-03-08 2005-01-14 Vivalis Lignees de cellules aviaires utiles pour la production de substances d'interet
US6919426B2 (en) 2002-09-19 2005-07-19 Amgen Inc. Peptides and related molecules that modulate nerve growth factor activity
WO2005032457A2 (en) 2003-07-21 2005-04-14 Boyce Thompson Institute For Plant Research, Inc. Vectors and methods for immunization against norwalk virus using transgenic plants
EP1500699A1 (en) 2003-07-22 2005-01-26 Vivalis Production of vaccinia virus with adherent or non adherent avian cell lines
US7902338B2 (en) 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
JP2007537137A (ja) 2003-09-24 2007-12-20 モンタナ ステート ユニバーシティ ノロウィルスモノクローナル抗体及びペプチド
EP1528101A1 (en) 2003-11-03 2005-05-04 ProBioGen AG Immortalized avian cell lines for virus production
CN1989250B (zh) 2004-05-18 2013-11-20 阿尔法瓦克斯公司 Tc-83衍生的甲病毒属载体、颗粒和方法
US7691368B2 (en) 2005-04-15 2010-04-06 Merial Limited Vaccine formulations
BRPI0611336A2 (pt) 2005-06-01 2010-08-31 Dow Global Technologies Inc método para produzir uma partìcula multivalente semelhante a vìrus, partìcula multivalente semelhante a vìrus, método de aumentar a solubilidade de uma partìcula multivalente semelhante a vìrus e vacina
ES2514316T3 (es) 2005-11-22 2014-10-28 Novartis Vaccines And Diagnostics, Inc. Partículas similares a virus (VLPs) de Norovirus y Sapovirus
WO2008016391A2 (en) 2006-01-31 2008-02-07 The Board Of Trustees Of The Leland Stanford Junior University Self-complementary parvoviral vectors, and methods for making and using the same
ES2602610T3 (es) 2007-05-31 2017-02-21 Medigene Ag Proteína estructural mutada de un parvovirus
CN104740624B (zh) * 2007-09-18 2018-04-24 武田疫苗股份有限公司 赋予针对诺如病毒的保护性免疫应答的疫苗
CN101153341B (zh) * 2007-09-21 2010-12-15 珠海市疾病预防控制中心 诺如病毒gⅱ型检测用引物、检测方法、检测试剂盒
CN102015651B (zh) 2008-03-03 2014-12-31 Irm责任有限公司 作为tlr活性调节剂的化合物和组合物
US8877908B2 (en) 2008-07-11 2014-11-04 The Administrators Of The Tulane Educational Fund Stimulus-responsive apta chelamers
NO2324113T3 (enExample) * 2008-08-08 2018-07-28
BRPI0918670B8 (pt) 2008-09-17 2021-05-25 Xencor Inc anticorpo
TWI496582B (zh) 2008-11-24 2015-08-21 必治妥美雅史谷比公司 雙重專一性之egfr/igfir結合分子
JP5611222B2 (ja) 2008-11-26 2014-10-22 アムジエン・インコーポレーテツド アクチビンiib受容体ポリペプチドの変異体及びその使用

Similar Documents

Publication Publication Date Title
JP2013533745A5 (enExample)
Kis et al. Emerging technologies for low‐cost, rapid vaccine manufacture
JP2011152137A5 (enExample)
JP2014221052A5 (enExample)
JP2011182797A5 (enExample)
CN104781413B (zh) 用于具有肺炎球菌血清型的荚膜多糖的生产方法
WO2021088825A1 (zh) F基因型腮腺炎病毒减毒株及构建方法和应用
CN106399350A (zh) 一种猪圆环病毒ii型病毒样颗粒疫苗及其制备方法
CN107267532A (zh) PEDV JS2008株全长感染性cDNA的构建方法及应用
CN105779444B (zh) 一种提高芽孢杆菌蛋白表达量的串联启动子
CN103333849B (zh) 金黄色葡萄球菌突变株及其制备方法和应用
JP2023024998A5 (enExample)
CN103923943B (zh) 一种基于腺病毒AdC7的表达载体及其构建方法
CN111218477B (zh) 靶向感染哺乳动物细胞的禽4型腺病毒载体及其应用
JP2014530609A5 (enExample)
CN104404057B (zh) 一种大鲵虹彩病毒病疫苗及制备方法和应用
Cantarella et al. Recombinant measles virus-HPV vaccine candidates for prevention of cervical carcinoma
CN105349562B (zh) 表达猪细小病毒vp2蛋白的重组载体、重组菌及其应用
CN104046586A (zh) 一株基因工程菌及其在生产(2r,3r)-2,3-丁二醇中的应用
Krammer et al. Influenza virus-like particles as an antigen-carrier platform for the ESAT-6 epitope of Mycobacterium tuberculosis
JP2015507472A5 (enExample)
CN106905434B (zh) 一种包含蹄蝠肝炎病毒核心蛋白的重组融合蛋白及其制备方法和应用
KR100959145B1 (ko) 인유두종바이러스 바이러스 유사 입자의 생산 및 정제 방법
CN116217738B (zh) 禽腺病毒病四价嵌合病毒样颗粒及其制备方法和应用
CN103215216B (zh) 黑色素瘤治疗性质粒DNA疫苗pSVK-CAVA的制备方法及其专用工程菌及发酵培养基